Wamika Pharmaceuticals Pvt. Ltd. - Due diligence report

A 360° intelligence report on Wamika Pharmaceuticals Pvt. Ltd.: trust score, financial health, credit view, compliance, directors, growth an…

2001-05-23 Na, Haryana Active Unlisted Active Compliant
Share
Connect MCP
WP Wamika Pharmaceuticals Pvt. Ltd.
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Wamika Pharmaceuticals Pvt. Ltd. — 360° Intelligence Report

Generated from MCA filings & public records
83/100
Trust Score
Low Risk

Wamika Pharmaceuticals Pvt. Ltd. is assessed as Low Risk with a Trust Score of 83/100. Wamika Pharmaceuticals Pvt. Ltd. is an active private limited indian non-government company incorporated in 2001, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.

Report generated on 08 Aug 2026 from the latest processed filings. Wamika Pharmaceuticals Pvt. Ltd. snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
83/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
100/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
75/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
55/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreModerate
60/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
75/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
75/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 55/100 Moderate
  • Liabilities ≈ 38% EBITDA - stretched.
  • Working-capital cover adequate.
  • Profitable - internal accruals available.

Charges position: 1 open (78.00 Lakh) · 0 satisfied (-).

Banking relationships (from registered charges)
LenderChargesAmount
Oriental Bank Of Commerce1 48.0 cr
Compliance Score: 100/100 Low Risk
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 60/100
NameDIN / PANDesignationAppointedTenureDIN status
NAVEEN KUMAR GARG 01234567 Director 01/04/2018 6 yrs Approved
  • Board below statutory minimum.
  • No disqualified or deactivated DINs.
  • 1 director exit(s) in the last 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
-

Promoters hold the largest single block of equity - exact percentages are part of the full report.

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 75 · Distress 75
Growth signals & trust indicators
Revenue acceleration: +1.42 over 4 year(s).
Net margin improved to 2.1x.
Operating for 25+ years.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
1 open charge(s) registered - assets are encumbered.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence87/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 1 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment72/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 1 open charge(s) of 78.00 Lakh already registered.
  • Compliance record supports lending.
Investor view77/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 2 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management churn warrants questions.
09

MCA Filings & Events Timeline

Latest 6 events
11 Jan 2026
Director ceased
PARVEEN KUMAR GARG
30 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
18 Oct 2011
Charge created
Oriental Bank Of Commerce - 78.00 Lakh
23 May 2001
Incorporated
Registered with Roc Delhi
Director appointed
NAVEEN KUMAR GARG (Director)
10

Key Observations

Auto-generated from the data above
Revenue grew 24% over the last 4 financial year(s).
Net profit margin moved from 0.86 to 61%.
Debt-to-equity stands at 38% - leverage worth monitoring.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
1 active director(s) / partner(s); review board churn before relying on management continuity.
1 active GST registration(s) indicate ongoing business operations.
Promoters hold the largest single block of equity as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Aaron Babcon (India) Pvt Ltd U24234WB1980PTC032776 Kolkata, West Bengal, India
Espee Formulation Private Limited U24231GJ1988PTC011043 Rajkot, Gujarat, India
Bini Organics Private Limited U24200MH1997PTC107552 Mumbai 400 064, Maharashtra, India
Nandesari Drugs And Pharmaceuticals Private Limited U24230DL2021PTC384483 Delhi, Delhi, India
Jvs Healthcare Private Limited U85100DL2010PTC199182 Civil Lines, Delhi, India
Hindocare (India) Private Limited U24297KA2019PTC128945 Kapu, Karnataka, India
Belgaum Poly Organic Fertilizers Private Limited U24219KA2006PTC039564 Nipani, Karnataka, India
Samy Organics Private Limited U24304AP2021PTC117906 Guntur, Andhra Pradesh, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Wamika Pharmaceuticals Pvt. Ltd. before audits and certifications: compliance score 100/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Wamika Pharmaceuticals Pvt. Ltd.: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Favourable lending indicators. Credit risk score 55/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 75/100, margin trends, ownership structure and peer set for Wamika Pharmaceuticals Pvt. Ltd. - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 83/100, distress signals and MSME payment-delay disclosures - know whether Wamika Pharmaceuticals Pvt. Ltd. pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Wamika Pharmaceuticals Pvt. Ltd. - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Wamika Pharmaceuticals Pvt. Ltd. an active company?

Wamika Pharmaceuticals Pvt. Ltd. has MCA status “Active” with a compliance score of 100/100 (Low Risk).

Is Wamika Pharmaceuticals Pvt. Ltd. financially healthy?

Wamika Pharmaceuticals Pvt. Ltd. has a Financial Health Score of 75/100 (Low Risk) based on its filed financial statements.

Should I do business with Wamika Pharmaceuticals Pvt. Ltd.?

Its overall Trust Score is 83/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Wamika Pharmaceuticals Pvt. Ltd.?

Promoters hold the largest single block of equity - exact percentages are in the full report. 1 active director(s) are on record.

Does Wamika Pharmaceuticals Pvt. Ltd. have loans or charges against its assets?

1 open charge(s) are registered against its assets.

Is Wamika Pharmaceuticals Pvt. Ltd. up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 100/100 (Low Risk).

Is it risky to lend to Wamika Pharmaceuticals Pvt. Ltd.?

Its Credit Risk Score is 55/100 (Moderate). Banker verdict: Favourable lending indicators.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.